366790-50-3

Basic information

• Product Name: 4-(broMoMethyl)-2-fluorobenzonitrile
• Synonyms: Benzonitrile, 4-(2-broMoacetyl)-2-fluoro-;4-(2-bromoacetyl)-2-fluorobenzonitrile
• CAS NO: 366790-50-3
• Molecular Formula: C₉H₅BrFNO
• Molecular Weight: 214.0344032
• Mol File: 366790-50-3.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(broMoMethyl)-2-fluorobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(broMoMethyl)-2-fluorobenzonitrile(366790-50-3)
• EPA Substance Registry System: 4-(broMoMethyl)-2-fluorobenzonitrile(366790-50-3)

Safety Data

• Hazardous Substances Data: 366790-50-3(Hazardous Substances Data)

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 176508-81-9 4-cyano-3-fluorobenzoic acid 
• 177787-22-3 4-cyano-3-fluoro-benzoyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 214760-18-6 4-acetyl-2-fluoro-benzonitrile 

Downstream Products

• 872017-92-0 (S)-tert-butyl 1-(4-(4-cyano-3-fluorophenyl)-1H-imidazol-2-yl)-2-phenylethylcarbamate 
• 872018-14-9 (S)-2-benzyloxycarbonylamino-pentanedioic acid 5-tert-butyl ester 1-[2-(4-cyano-3-fluoro-phenyl)-2-oxo-ethyl]ester 
• 1035018-26-8 tert-butoxycarbonylamino-acetic acid 2-(4-cyano-3-fluoro-phenyl)-2-oxo-ethyl ester 
• 872018-43-4 (S)-2-(4-cyano-3-fluorophenyl)-2-oxoethyl 2-(tertbutoxycarbonylamino)-3-phenylpropanoate 
• 1007315-24-3 2-fluoro-4-{2-[(2-hydroxy-1,1-dimethylethyl)amino]-1,3-thiazol-4-yl}benzonitrile 

Relevant articles and documents

Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity

Novel inhibitors of FXIa containing an (S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine core have been optimized to provide compound 16b, a potent, reversible inhibitor of FXIa (Ki = 0.3 nM) having in vivo antithrombotic efficacy in the rabbit AV-shunt thrombosis model (ID50 = 0.6 mg/kg + 1 mg kg-1 h-1). Initial analog selection was informed by molecular modeling using compounds 11a and 11h overlaid onto the X-ray crystal structure of tetrahydroquinoline 3 complexed to FXIa. Further optimization was achieved by specific modifications derived from careful analysis of the X-ray crystal structure of the FXIa/11h complex. Compound 16b was well tolerated and enabled extensive pharmacologic evaluation of the FXIa mechanism up to the ID90 for thrombus inhibition.

IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH

The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

Tricyclic oxazolidone derivatives useful as PR modulators

Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are use